Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shares hit a new 52-week high and low during mid-day trading on Tuesday . The company traded as low as $9.95 and last traded at $10.00, with a volume of 11731 shares changing hands. The stock had previously closed at $10.30.
PRTK has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 6th. BidaskClub cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 24th. HC Wainwright increased their target price on shares of Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a report on Friday, March 2nd. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 9th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.00.
Get Paratek Pharmaceuticals alerts:The stock has a market cap of $325.44 million, a P/E ratio of -3.09 and a beta of 0.49. The company has a current ratio of 8.06, a quick ratio of 8.06 and a debt-to-equity ratio of 0.47.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.03. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. research analysts expect that Paratek Pharmaceuticals, Inc. will post -3.65 EPS for the current fiscal year.
In other news, Chairman Michael Bigham sold 8,700 shares of the stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $12.70, for a total value of $110,490.00. Following the sale, the chairman now directly owns 199,730 shares in the company, valued at $2,536,571. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Evan Loh sold 8,084 shares of the stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $12.70, for a total transaction of $102,666.80. Following the completion of the sale, the chief operating officer now owns 214,786 shares in the company, valued at $2,727,782.20. The disclosure for this sale can be found here. Insiders sold 27,721 shares of company stock worth $352,057 over the last quarter. Company insiders own 6.20% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Paratek Pharmaceuticals by 6.6% in the first quarter. BlackRock Inc. now owns 2,028,845 shares of the specialty pharmaceutical company’s stock valued at $26,374,000 after purchasing an additional 125,194 shares during the last quarter. Highland Capital Management LP boosted its position in Paratek Pharmaceuticals by 320.9% during the first quarter. Highland Capital Management LP now owns 959,278 shares of the specialty pharmaceutical company’s stock worth $12,471,000 after acquiring an additional 731,378 shares during the last quarter. Renaissance Technologies LLC boosted its position in Paratek Pharmaceuticals by 21.6% during the fourth quarter. Renaissance Technologies LLC now owns 450,649 shares of the specialty pharmaceutical company’s stock worth $8,067,000 after acquiring an additional 79,911 shares during the last quarter. Northern Trust Corp boosted its position in Paratek Pharmaceuticals by 13.0% during the first quarter. Northern Trust Corp now owns 361,406 shares of the specialty pharmaceutical company’s stock worth $4,698,000 after acquiring an additional 41,608 shares during the last quarter. Finally, Royce & Associates LP boosted its position in Paratek Pharmaceuticals by 22.9% during the fourth quarter. Royce & Associates LP now owns 360,269 shares of the specialty pharmaceutical company’s stock worth $6,449,000 after acquiring an additional 67,069 shares during the last quarter. Institutional investors and hedge funds own 77.40% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
No comments:
Post a Comment